CA2985897C — Drippable ophthalmic bimatoprost gel
Assigned to MEDPROJECT PHARMA-ENTWICKLUNGS- und VERTRIEBSGESELLSCHAFT MBH · Expires 2019-10-01 · 7y expired
What this patent protects
The invention refers to a drippable ophthalmic gel, said gel having a composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of > 0.2 % by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC…
USPTO Abstract
The invention refers to a drippable ophthalmic gel, said gel having a composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of > 0.2 % by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10 % by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.